EAN 2026 | Current limits of L-DOPA therapy in PD and approaches to optimization
Francesca Morgante
• 27 Jun 2026
Francesca Morgante, MD, PhD, St George’s University of London, London, United Kingdom, discusses the current limits of levodopa (L-DOPA) therapy and emerging approaches to optimize this strategy. Prof. Morgante highlights that changes in the response to L-Dopa across the disease course, as well as gastrointestinal disturbances, are the key limitations. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
